Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience, Inc. reported its Q4 2025 earnings, demonstrating strong growth in revenue driven by increased demand for its cannabinoid-based pharmaceuticals. The company's innovative research and successful product launches in pain management and glaucoma treatment have attracted positive investor sentiment. Guidance for the next quarter suggests continued revenue growth, despite some operational challenges faced due to regulatory hurdles. Management also highlighted strategic partnerships that could enhance their market position. Overall, the earnings call reflected a confident outlook for future profitability.